Updating results

215 results

Sort: Relevance | Date

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults

Technology appraisal guidance Published March 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Naltrexone–bupropion for managing overweight and obesity (TA494)

Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults

Technology appraisal guidance Published December 2017

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer

Technology appraisal guidance Published August 2019

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment (with trastuzumab and chemotherapy) of HER2-positive early stage breast cancer

Technology appraisal guidance Published March 2019

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

This guidance has been updated and replaced by NICE technology appraisal guidance 616.

Technology appraisal guidance Published December 2017

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

This guidance has been updated and replaced by NICE technology appraisal guidance 531.

Technology appraisal guidance Published June 2017

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been updated and replaced by NICE technology appraisal guidance 524.

Technology appraisal guidance Published June 2017

Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

Technology appraisal guidance Published April 2017

Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

Technology appraisal guidance Published August 2017

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

This guidance has been updated and replaced by NICE technology appraisal guidance 555.

Technology appraisal guidance Published March 2018